The University of Chicago Header Logo

Connection

Bruce Brockstein to Carcinoma, Squamous Cell

Back to Details
This is a "connection" page, showing publications Bruce Brockstein has written about Carcinoma, Squamous Cell.
Bruce Brockstein
Connection Strength
2.226
Carcinoma, Squamous Cell
  1. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2016 Aug; 16(8):847-58.
    View in: PubMed
    Score: 0.342
  2. Management of recurrent head and neck cancer: recent progress and future directions. Drugs. 2011 Aug 20; 71(12):1551-9.
    View in: PubMed
    Score: 0.244
  3. Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol. 2010 Nov; 7(11):616-8.
    View in: PubMed
    Score: 0.231
  4. Organ preservation for advanced head and neck cancer concomitant chemoradiation. Cancer Treat Res. 2003; 114:235-48.
    View in: PubMed
    Score: 0.134
  5. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs. 2001; 19(3):249-54.
    View in: PubMed
    Score: 0.117
  6. Reduction of distant metastases in head and neck cancer with concomitant chemotherapy. J Clin Oncol. 2000 Sep 15; 18(18):3320-1.
    View in: PubMed
    Score: 0.114
  7. Benefits of chemotherapy in head and neck cancer. Lancet. 2000 Aug 26; 356(9231):767-8.
    View in: PubMed
    Score: 0.114
  8. Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled? Curr Opin Oncol. 2000 May; 12(3):221-8.
    View in: PubMed
    Score: 0.111
  9. Association of a Proactive Swallowing Rehabilitation Program With Feeding Tube Placement in Patients Treated for Pharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2018 06 01; 144(6):483-488.
    View in: PubMed
    Score: 0.098
  10. A Contemporary Analysis of Surgical Trends in the Treatment of Squamous Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the National Cancer Database. Ann Surg Oncol. 2015 Dec; 22(13):4422-31.
    View in: PubMed
    Score: 0.079
  11. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
    View in: PubMed
    Score: 0.078
  12. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
    View in: PubMed
    Score: 0.075
  13. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1391-8.
    View in: PubMed
    Score: 0.066
  14. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 01; 115(19):4504-13.
    View in: PubMed
    Score: 0.054
  15. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
    View in: PubMed
    Score: 0.043
  16. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73.
    View in: PubMed
    Score: 0.041
  17. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
    View in: PubMed
    Score: 0.041
  18. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
    View in: PubMed
    Score: 0.037
  19. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
    View in: PubMed
    Score: 0.036
  20. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.034
  21. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.034
  22. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
    View in: PubMed
    Score: 0.030
  23. Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. Invest New Drugs. 2000 Aug; 18(3):261-3.
    View in: PubMed
    Score: 0.028
  24. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
    View in: PubMed
    Score: 0.026
  25. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
    View in: PubMed
    Score: 0.012
  26. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.